ADVM Adverum Biotechnologies
- 9.6100
- -0.2000-2.04%
- 9.6500
- +0.0400+0.42%
Adverum Biotechnologies News
Adverum Biotechnologies (ADVM.US): The 2024 Q1 financial report achieved revenue of $0, previously $3.6 million; earnings per share were -1.50 dollars, previous value was -2.90 dollars, and expected value was -1.41 dollars.
Adverum Biotechnologies (ADVM.US): The 2024 Q1 financial report achieved revenue of $0, previously $3.6 million; earnings per share were -1.50 dollars, previous value was -2.90 dollars, and expected value was -1.41 dollars.
Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate of $(1.40) by 7.14 percent.
Adverum Biotechnologies | 10-Q: Quarterly report
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
Adverum Biotechnologies a New Buy at H.C. Wainwright on Wet AMD Gene Therapy
Adverum Biotechnologies (ADVM.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $30.00.
Adverum Biotechnologies (ADVM.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $30.00.
HC Wainwright & Co. Initiates Coverage On Adverum Biotechnologies With Buy Rating, Announces Price Target of $30
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rating and announces Price Target of $30.
Mizuho Bank: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $40.00 to $22.00.
Mizuho Bank: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $40.00 to $22.00.
Mizuho Maintains Buy on Adverum Biotechnologies, Lowers Price Target to $22
Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies with a Buy and lowers the price target from $40 to $22.
Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compan
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Files for $200M Mixed Securities Shelf
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Positive Outlook for Adverum Biotechnologies With Upcoming Ixo-vec Milestones and Strong Financial Position
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Analysis
Price Target
No Data
